Why this ASX 200 stock could be a bargain buy after crashing 13%

Bell Potter thinks that a buying opportunity could have opened up for investors.

Sonic Healthcare Ltd (ASX: SHL) shares certainly had a day to forget on Thursday.

The ASX 200 healthcare stock crashed 13% to end the session at $25.05.

This was driven by a negative reaction to the release of its full year results for FY 2025.

While this is disappointing, one leading broker believes that the selloff could have created a buying opportunity for investors.

A woman presenting company news to investors looks back at the camera and smiles.

Image source: Getty Images

What is the broker saying about this ASX 200 stock?

Bell Potter notes that Sonic Healthcare's operating profit (EBITDA) in FY 2025 was modestly short of expectations, which was punished by the market. It said:

Despite over 7% revenue and EBITDA growth, NPAT Post MI was relatively flat with a higher-than-expected tax rate reflecting the mix of earnings across jurisdictions. The EBITDA result was lower than BPe by c.1.4% and consensus by c.2.0%, which disappointed the market with a c.13% sell-off of the share price on the result.

Looking ahead, the broker was pleased to see the ASX 200 stock guiding to strong earnings growth in FY 2026. It adds:

EBITDA growth guidance of up c.17% and c.19% at the EPS line at current FX rates reflect in part the impact of the LADR acquisition, as well as the announced Cairo Diagnostics business. We have made minor adjustments to our estimates that mostly reflect higher interest cost estimates.

Major upside potential

According to the note, the broker has reaffirmed its buy rating on the ASX 200 stock with a trimmed price target of $33.30 (from $33.70).

Based on its current share price of $25.05, this implies potential upside of 33% for investors over the next 12 months.

To put this into context, a $10,000 investment would turn into approximately $13,300 if Bell Potter is on the money with its recommendation.

But the returns won't stop there. The broker believes that Sonic Healthcare will increase its dividend to $1.09 per share in FY 2025. This represents an attractive 4.4% dividend yield, which lifts the total potential return to over 37%.

Commenting on its buy recommendation, the broker said:

Investment View: BUY; TP Reduced 1.2% to $33.30 / sh. Changes to working capital and interest expense estimates drive a c.1.2% reduction in our blended valuation to $33.30/sh. Despite the market reaction, we think the share price offers material upside for investors that appreciate steady compound earners.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Sonic Healthcare. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Male and female scientists analysing data on a computer.
Healthcare Shares

Why I'd buy this ASX biotechnology company over CSL

The potential for research-driven growth could be large.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

ResMed or Cochlear: Which ASX healthcare share would I buy today?

I like both businesses for the long term, but their recent financial performances have given me something to think about.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Could Telix Pharmaceuticals shares double in value over the next 12 months?

Find out if the ASX biotech stock is a buy, sell, or hold now.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

3 compelling reasons to consider buying Mesoblast shares

This company has a lot going on, plus strong revenues.

Read more »

Doctor with stethoscope typing on her computer.
Healthcare Shares

Are CSL shares a buy, hold, or sell at their 52-week high?

Investors have become much more optimistic about its future. But has the share price recovery gone too far?

Read more »